Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
TransGlobe Energy Corporation Announces Its Participation in the Virtual Summer Summit
-
Bill.com (BILL) Announces Launch of 3.25M Share Proposed Follow-on Offering of Common Stock
-
Bill.com Announces Launch of Proposed Follow-on Offering
-
Sundial Announces Successful Amendments with Senior Lenders, US$18 Million Convertible Notes Issuance and Close of Bridge Farm Sale
-
'Stay at home stock' Slack Technologies dips ahead of report
-
3iQ’s Bitcoin Fund Files New Issue Prospectus
-
ZoomInfo Technologies (ZI) IPO Opens 90% Higher
-
InterRent REIT Closes $230 Million Bought Deal Financing
-
Oncolytics Biotech (ONCY) Provides Recap of KOL Call Highlighting Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
-
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
-
UPDATE: ZoomInfo Technologies Inc. (ZI) Prices 44.5M Class A Share IPO at $21/Sh
-
ZoomInfo Announces Pricing of its Initial Public Offering
-
DraftKings Inc. (DKNG) PT Raised to 'Street High' $50 at Canaccord Genuity (Earlier)
-
TransGlobe Energy Corporation Announces Director/PDMR Shareholdings
-
Canaccord Genuity Group Inc. Reports Fourth Quarter Fiscal 2020 Results
-
Net Asset Value(s)
-
Shamrock Capital Announces Acquisition of Adweek
-
Kaleido Biosciences Inc. (KLDO) Prices 4.75M Share Common Offering at $7.50/Sh
-
Allogene Therapeutics (ALLO) Prices 11.7M Share Common Offering at $47/Sh
-
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
-
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
-
Form X-17A-5 CANACCORD GENUITY WEALTH For: Mar 31
-
Kaleido Biosciences Inc. (KLDO) to Offer Common Stock
-
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
-
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
-
Form X-17A-5 CANACCORD GENUITY LLC For: Mar 31
-
Total voting rights
-
Schultze Special Purpose Acquisition Corp. (SAMA) Announces Non-Binding Letter of Intent for Business Combination with Clever Leaves
-
Schultze Special Purpose Acquisition Corp. Announces Non-Binding Letter of Intent for a Business Combination with Clever Leaves, a Leading Pharmaceutical-Grade Multi-National Cannabis Operator
-
Atalaya Mining PLC Announces Junta de Andalucía Validates Mining Permits
-
Canaccord Genuity Assumes Bandwidth Inc. (BAND) at Buy
-
Canaccord Genuity Assumes Twilio (TWLO) at Buy
-
Canaccord Genuity Assumes Everbridge (EVBG) at Buy
-
Aleafia Health Announces Closing of $14.95 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
-
Repay Holdings Corporation (RPAY) Prices 8M Share Common Offering at $20/Sh
-
TransGlobe Energy Corporation Announces Director/PDMR Shareholdings
-
REPAY Announces Pricing of Public Offering of Common Stock
-
Renewable Energy Group (REGI) PT Raised to $44 at Canaccord Genuity
-
HEICO (HEI) PT Raised to $100 at Canaccord Genuity Following 2Q
-
Autodesk (ADSK) PT Raised to $230 at Canaccord Genuity
-
Penumbra, Inc. (PEN) Prices 753K Share Common Offering at $166/Sh
-
Atalaya Mining PLC Announces Notice for the AGM in light of COVID-19
-
Penumbra, Inc. Announces Pricing of Offering of Common Stock
-
Pelangio Exploration Completes Final Tranche of Previously Announced Private Placement for Total Aggregate Gross Proceeds of Approximately $1,450,000
-
Inari Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Net Asset Value(s)
-
Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals
-
Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals

